BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Max Gelman

Senior Editor

Amid the brouhaha over Alnylam’s disappointing and perhaps confusing HELIOS-B data presentation last week, competitor BridgeBio is — at least publicly — attempting to stay above the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu

Max Gelman

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

In surprise, study suggests Covid mRNA vaccines may boost cancer immunotherapy efficacy

Scorpion details early data on targeted breast cancer drug as it seeks to challenge Novartis, Roche

FDA approves subcutaneous Ocrevus, broadening access to Roche and Genentech blockbuster

SEC probe of Illumina’s Grail deal targets sales forecasts, sources say

Post-Hoc: Big promises built Moderna. They might also be its undoing

Arbor Biotechnologies cuts early-stage discovery work, lays off staff

Bridge­Bio sticks to script for AT­TR-CM as Al­ny­lam cleans up ‘ty­po’ sna­fu

Senior Editor

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

BridgeBio sticks to script for ATTR-CM as Alnylam cleans up ‘typo’ snafu